BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced that it has completed an additional $3 million private note and warrant placement with the sale of securities to private investors led by Cross Atlantic Capital Partners and Stewart Greenebaum.
